DelveInsight’s “Primary Open Angle Glaucoma (POAG) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Open Angle Glaucoma Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Primary Open Angle Glaucoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Primary Open Angle Glaucoma (POAG): An Overview
Glaucoma describes a group of conditions in which there is characteristic cupping of the optic disc with corresponding visual field defects due to retinal ganglion cell loss. It is a progressive condition and the most common cause of irreversible blindness worldwide.
The two major categories of glaucoma are open-angle glaucoma (OAG) and narrow-angle glaucoma. The OAG is primarily divided into two subtypes, i.e., Primary open-angle glaucoma (POAG) and Secondary open-angle glaucoma.
POAG is classified based on the age of onset as primary congenital glaucoma (onset up to 3 years of age), juvenile open-angle glaucoma (JOAG; onset at 5–35 years), and adult-onset POAG (after the age of 35 years).
Primary Open Angle Glaucoma Market Key Facts
-
According to the American Academy of Ophthalmology Primary open-angle glaucoma (POAG) is responsible for 12.3% of blindness worldwide. People in their 70s have a 3 to 8 times higher prevalence of POAG. As the population ages, the total number of glaucoma patients will continue to rise.
-
In 2020, the total prevalent population of Glaucoma in the US was estimated to be 3,210,374.
-
Among the 7MM, the most diagnosed prevalent cases of Primary Open Angle Glaucoma were recorded in the United States, while the lowest prevalent population of POAG was recorded in Spain.
-
Among the EU5 countries, Germany has the highest diagnosed prevalent population of Primary Open Angle Glaucoma, followed by Italy.
-
It is observed that Primary Open Angle Glaucoma accounts for 90% of open-angle Glaucoma cases.
Primary Open Angle Glaucoma (POAG) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Primary Open Angle Glaucoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report details the Primary Open Angle Glaucoma market trend for each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.
Primary Open Angle Glaucoma (POAG) Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Primary Open Angle Glaucoma (POAG) Epidemiology Segmentation
-
Total Prevalent Population of Glaucoma
-
Total Diagnosed Prevalent Population of OAG
-
Gender-specific Diagnosed Prevalence of POAG
-
Age-specific Diagnosed Prevalence of POAG
-
Total Diagnosed Prevalent Population of POAG
Primary Open Angle Glaucoma (POAG) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Open Angle Glaucoma market or expected to get launched during the study period. The analysis covers Primary Open Angle Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Primary Open Angle Glaucoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/primary-open-angle-glaucoma-poag-market
Primary Open Angle Glaucoma (POAG) Therapeutics Analysis
There are approx. 10+ key companies which are developing therapies for Primary Open Angle Glaucoma (POAG). Currently, Laboratorios Sophia S.A de C.V. has its Primary Open Angle Glaucoma (POAG) drug candidates in the most advanced stage of clinical development.
Some of the key companies in the Primary Open Angle Glaucoma (POAG) Therapeutics Market include:
• Laboratorios Sophia S.A de C.V
• Aerie Pharmaceuticals
• Santen Pharmaceuticals
• Chong Kun Dang Pharmaceutical
• MediPrint Ophthalmics, Inc.
• Aerpio Therapeutics
• Whitecap Biosciences, LLC
• Occular Therapeutics
And many others
Primary Open Angle Glaucoma (POAG) Emerging Drugs Covered in the report include:
PRO-122: Laboratorios Sophia S.A de C.V.
DE-126: Santen Pharmaceuticals
And many more
Further product details are provided in the report. Download the sample pdf to learn more about emerging therapies and key companies in the domain:
https://www.delveinsight.com/sample-request/primary-open-angle-glaucoma-poag-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Primary Open Angle Glaucoma Competitive Intelligence Analysis
4. Primary Open Angle Glaucoma Market Overview at a Glance
5. Primary Open Angle Glaucoma Disease Background and Overview
6. Primary Open Angle Glaucoma Patient Journey
7. Primary Open Angle Glaucoma Epidemiology and Patient Population
8. Primary Open Angle Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Open Angle Glaucoma Unmet Needs
10. Key Endpoints of Primary Open Angle Glaucoma Treatment
11. Primary Open Angle Glaucoma Marketed Products
12. Primary Open Angle Glaucoma Emerging Therapies
13. Primary Open Angle Glaucoma Seven Major Market Analysis
14. Attribute Analysis
15. Primary Open Angle Glaucoma Market Outlook (7 major markets)
16. Primary Open Angle Glaucoma Access and Reimbursement Overview
17. KOL Views on the Primary Open Angle Glaucoma Market.
18. Primary Open Angle Glaucoma Market Drivers
19. Primary Open Angle Glaucoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/primary-open-angle-glaucoma-poag-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Reports by DelveInsight
Audiology Devices Market
“Audiology Devices Market” research report provides comprehensive insights into the historical and forecasted market size, share, trends, and growth estimation for the Audiology Devices. It also covers the latest breakthroughs, collaboration, latest innovations, emerging devices, and key companies working in the global Audiology Devices market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/